Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow.

Anzhi Hu, Huijuan Chen, Jing Liang, Cong Liu, Fanzhu Li, Chaofeng Mu

Journal of controlled release : official journal of the Controlled Release Society 2021 Nov 10

filter terms:

Cell-based therapies could overcome the limitations of traditional drugs for the treatment of refractory diseases. Cell exchange between the bone marrow and blood is bidirectional. Several kinds of cells in the blood have the capability to enter the bone marrow by interacting with sinusoidal cells under specific physiological or pathological conditions. These cells are the potential living therapeutics or delivery vehicles to treat or prevent bone marrow-related hematologic diseases. In this review, we summarized the in vivo molecular mechanisms and kinetics of these cells in entering the bone marrow. The advances in the fabrication of living cell drugs and the strategies to design cell-based carriers into the bone marrow were discussed. The latest studies on how to use blood cells as living drugs or as drug carriers to improve therapeutic outcomes of hematologic diseases inside the bone marrow were highlighted. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Anzhi Hu, Huijuan Chen, Jing Liang, Cong Liu, Fanzhu Li, Chaofeng Mu. Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow. Journal of controlled release : official journal of the Controlled Release Society. 2021 Nov 10;339:1-13